Study of AEF0217 for people with Down syndrome
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study tests if an investigational drug called AEF0217 can help improve thinking and daily living skills in people with Down syndrome. It's for ages 16-32 who have a caregiver to support them throughout the trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Down syndrome (full trisomy 21 or a translocation type, not mosaic).
- You need to be between 16 and 32 years old.
- A parent or caregiver must go with you to all visits and help you follow the study plan.
- You must be able to walk on your own and have enough vision and hearing for the tests.
- You cannot have epilepsy or a history of seizures (except one mild fever seizure more than 8 years ago).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the effects of a medication called AEF0217 in people with Down syndrome. It is for participants who have already completed an earlier study of AEF0217 and their caregivers.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
This study tests a drug called ublituximab, given as an IV infusion, for adults with Down syndrome who have developed regression disorder and haven't fully improved with standard treatments. The goal is to see if this treatment can help improve daily functioning and quality of life.
This study looks at thinking skills (like memory and problem-solving) in adults with intellectual disabilities, including Down syndrome. You will complete some tests and interviews with a psychologist to understand how these skills work.
This study looks at how eating patterns and body composition relate to fatty liver in children and young adults with Trisomy 21 (Down syndrome) or other genetic intellectual disabilities. It may help understand who is at risk and how to prevent liver problems.
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
Hear when a new Down Syndrome (Trisomy 21) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.